All In Biotech

Drug Trial Radar · NCT03920072

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)

Last checked: Nov 20, 2026Latest source record: May 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

35

Actual

Start

Mar 7, 2019

Primary completion

Apr 7, 2022

Study completion Apr 7, 2022

Sponsor

Sponsor type
Industry
First posted
Apr 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).

Conditions

  • X-linked Hypophosphatemia

Interventions

  • BurosumabDrug

    Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving mean serum phosphorus levels above the LLN (2.5mg/dL[0.81mmol/L]), as averaged across dose cycles between baseline and their last administered dose.Time frame: Serum phosphorous levels will be monitored from Screening and every 12 weeks until the end of the study, at approximately 144 weeks.

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • CHU de Bicetre

    Le Kremlin-Bicêtre, France

  • Hopital Lariboisiere

    Paris, France

  • Hopital Cochin

    Paris, France

  • St. Vincent's University Hospital

    Dublin, Ireland

  • Azienda ospedaliera universitaria Careggi

    Florence, Italy

  • Western General Hospital

    Edinburgh, United Kingdom

  • National Hospital for Neurology and Neurosurgery-University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Nuffield Orthopaedic Centre - Oxford University Hospitals Nhs Trust

    Oxford, United Kingdom

  • Northen General Hospital

    Sheffield, United Kingdom

  • Royal National Orthopaedic Hospital NHS Trust

    Stanmore, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.